They suggested that the combination of FMT and anti-PD-1 altered the composition of the gut microbiome and tumor microenvironment to overcome resistance to anti-PD-1 in a subset of PD-1 advanced melanoma patients [28]. This evidence concerns the gene PDCD1 and melanoma.